(A) Timeline of the patient’s clinical events and interventions.

Slides:

Advertisements

Similar presentations

1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.

Advertisements

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Memorial Sloan-Kettering Cancer Center

Fluorescent In Situ Hybridization (FISH) to Identify Genetic Changes in Fine Needle Biopsy of Lung Lesions Prepared by Jin Jen NCI.

Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.

Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC  Paclitaxel with Trastuzumab.

Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.

Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Volume 52, Issue 1, Pages (July 2007)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

سرطان الثدي Breast Cancer

Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) analysis of MET and KRAS. For IHC, the specific MET antibody (Met (D1C2) XP Rabbit.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

FISH Analysis for the Detection of Lymphoma-Associated Chromosomal Abnormalities in Routine Paraffin-Embedded Tissue Roland A. Ventura, Jose I. Martin-Subero,

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Handling and Evaluation of Breast Cancer Biopsy

Predictive biomarker analyses in cytological specimens

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Progesterone receptor nuclear morphology patterns in breast cancer.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Detection rate for EGFR mutations in cfDNA.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves for overall survival (OS) probability.

Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.

Clinical courses of patients.

Detection rate of EGFR mutations in cfDNA by characteristics

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

Programmed cell death ligand-1 (PD-L1) immunohistochemistry for pulmonary adenocarcinoma tissues. Programmed cell death ligand-1 (PD-L1) immunohistochemistry.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Derivation and application of cancer‐specific epithelial‐mesenchymal transition (EMT) signature A six‐step scheme illustrating the generation of a cancer‐specific.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Change in individual tolerability assessment between baseline and study completion. Change in individual tolerability assessment between baseline and study.

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

(Handling and Evaluation of Breast Cancer Biopsy)

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

PRAME-specific CD4+ T-cell (TNF-α+/IFN-γ+) immunogenicity scores and cellular response prior to treatment and postdose 4 (ATP cohort for immunogenicity).

Clinical characteristics at diagnosis of brain metastases.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Detection of mutant alleles using ddPCR.

(A) Survival curves according to clinical response.

Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

(A) Timeline of the patient’s clinical events and interventions. (A) Timeline of the patient’s clinical events and interventions. (B) H&E of ductal non-special type (NST) (I) and micropapillary (V) components of the primary mixed invasive breast cancer. Immunostaining: Oestrogen and progesterone receptors are positive in about 10% of the nuclei of ductal NST (II and III) and in 70% (VI) and 40% (VII) of micropapillary subtype respectively. HER2 immunostaining is intense and complete (score 3+) in both histotypes (IV, VIII). (C) H&E staining of cell block section of fine needle aspiration (FNA) of supraclavicular lymph node showing micropapillary (blue) and glandular structures (yellow). (D) ERBB2 gene amplification by FISH in breast cancer cells. Red dots indicate the ERBB2 gene probe, and green signals represent the CEP17 reference probe. Magnification: 100x. (E) ddPCR analysis of matched plasma and CSF-derived ctDNA prior to T-DM1 treatment. BC, breast cancer; BSC, best supportive care; CSF, cerebrospinal fluid; ctDNA, circulating tumour DNA; EC-P, Epi-doxorubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 q21 days for four cycles followed by paclitaxel 175 mg/m2 q21days for four cycles; FFPE, formalin fixed, paraffin embedded; FISH, fluorescence in situ hybridisation; HERLAP, HERceptin or LAPatinib trial; OFS, ovarian function suppression; PD, progressive disease; RT, radiation therapy; T-DM1, trastuzumab emtansine; CNV, copy number variation. Giulia Siravegna et al. ESMO Open 2017;2:e000253 Copyright © European Society for Medical Oncology. All rights reserved.